Nicola Fracchiolla

University of Milan — Italy

Medicine · Health Sciences

32h-index4.5kcitations179works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(71), Acute Lymphoblastic Leukemia research(37), Chronic Myeloid Leukemia Treatments(26), Antifungal resistance and susceptibility(20), Chronic Lymphocytic Leukemia Research(19)

Publications178 total

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the <scp>AVALON</scp> study
British Journal of Haematology·2025Open Access
Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study
Blood·2025Open Access
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
Hematological Oncology·2025
Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity
Diagnostic Microbiology and Infectious Disease·2025
Real World Study on the Best <scp>CPX</scp> ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
American Journal of Hematology·2025· 3 citedOpen Access
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group
Annals of Hematology·2025Open Access
Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20+
Annals of Hematology·2025Open Access
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study
Annals of Hematology·2025Open Access
Matching-adjusted indirect comparison of CPX-351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study
2025Open Access
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
Cancer·2025· 2 citedOpen Access
P-2272. The CARV challenge: How do hematological malignancy patients struggle with diverse CARV pathogens
Open Forum Infectious Diseases·2025Open Access
Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
American Journal of Hematology·2025· 3 citedOpen Access
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: <scp>EPICOVIDEHA</scp>‐<scp>EPIFLUEHA</scp> Report
American Journal of Hematology·2024· 7 citedOpen Access
Donor Lymphocyte Infusions in Acute Lymphoblastic Leukemia: A Single-Center Retrospective Analysis
Blood·2024Open Access
Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level
Blood·2024Open Access
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group
Annals of Hematology·2024Open Access
Ponatinib alone or with chemo-immunotherapy in heavily pre-treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study
Haematologica·2024· 1 citedOpen Access
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial
Blood Advances·2024· 10 citedOpen Access
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission
Cancers·2024· 9 citedOpen Access
Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection·2024Open Access
page 1 of 9Next →

Frequent Co-authors

Livio Pagano(15), Chiara Cattaneo(13), Maria Ilaria Del Principe(13), Alessandro Busca(12), Mariarita Sciumé(12), Anna Candoni(12), Francesco Marchesi(11), Mario Delia(11), Antonino Neri(10), Agostino Cortelezzi(10), Francesca Farina(9), Márcio Nucci(8), Giulia Dragonetti(8), Jon Salmanton‐García(7), Luisa Verga(7), Barbora Weinbergerová(7), Jaap A. van Doesum(7), Marina Machado(7), Andreas Glenthøj(7), Ola Blennow(7)